🔗 Share this article

While the United States undertakes unprecedented adjustments to its immunization schedules, an unexpected name has surfaced unexpectedly: Høeg, a Danish American sports physician and public health researcher who rose to prominence by casting doubt on Covid vaccines during the global health crisis and has concentrated on potential deaths following Covid immunization in her short time at the FDA.

Planned Overhauls to Childhood Vaccine Schedule

Public health authorities planned to announce sweeping revisions to the pediatric vaccine schedule recently, synchronizing the US with the Danish immunization schedule, it is understood – a major change that would place the US out of step with many the world with no evidence for benefit. The planned update has been postponed until the next year.

In place of Vinay Prasad, Høeg is set to present at the gathering. She was newly appointed acting director of the FDA’s CDER, the fifth individual to run the division this year.

A Shift at the FDA

Høeg's temporary position might represent a closer partnership between the pharmaceutical and vaccine branches as Dr. Høeg and Prasad consolidate power at the FDA – and it suggests a increased emphasis upon reevaluating already-approved immunizations at the FDA.

Høeg has often pushed for discontinuing some pediatric immunization guidelines in the US so as to align more like the Danish model, a society with nationalized medicine and a population approximately the size of the state of Wisconsin.

In her initial comments, she has continued to focus on vaccines – traditionally the domain of Dr. Prasad, director of the FDA’s vaccine center – as opposed to drug regulation.

Questions Over Expertise

The appointee has no apparent experience in pharmaceutical research, approval processes or leadership, which has been customary for former heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the commissioner and CBER since spring.

“She appears not to have the necessary background” for running the drug-regulation department, stated Dr. Jonathan Howard. “She lacks experience running a clinical trial. She lacks experience in managing a major agency. She is not an expert in pharmaceutical oversight.”

Past heads of the center would “grasp legal statutes and the underlying principles of drug development”, said a former acting FDA commissioner. “Objectively, she doesn’t have the sort of resume that previous people who headed the center have had.”

The drug center has an enormous workload at the agency, she emphasized.

“The public just focuses on the innovative therapies, but the off-patent medication office clears thousands of generic medications. There is also a biosimilars division, OTC medication office and more, and all of those must be supervised,” Dr. Woodcock said. “The area you overlook, that’s the thing that I always told people is going to bite you.”

There is also, a major administrative aspect to the job, which supervises more than 5,000 employees. “It’s a huge administrative position, if you do it right,” she concluded.

Agency Reaction and Disputed Initiatives

Regarding questions about Dr. Høeg's qualifications and whether this appointment signifies greater collaboration among agency officials on vaccines, a spokesperson responded that the “inquiries are based on incorrect premises”.

“Her resume matches the functions of her job,” the spokesperson said, noting the time Høeg spent guiding the FDA commissioner on “pharmaceutical safety and oversight research, including predictive safety algorithms and shot safety tracking”.

In her interim role, Dr. Høeg assumes responsibility for the commissioner’s new expedited review system, a disputed one-day therapy clearance system that apparently worried her preceding directors. “By what process are these drugs being selected for this fast-track system? Who makes the choices?” Dr. Howard questioned. “There is a lot of lack of transparency happening at the agency right now.”

Overall, he said, “the FDA seems to be moving towards more relaxed rules of all drugs, except for vaccines.”

Established Track Record on Vaccines

Concerning vaccines, Høeg has a more established, if concerning, history, Howard said. She authored a analysis using unverified volunteer-provided data to determine the rate of myocarditis following COVID-19 vaccination. She consulted for the state of Florida chief medical officer Joseph Ladapo, who allegedly have modified findings to suggest Covid vaccines are riskier than they are.

Among her “wish list” for the current federal leadership featured revising regulations for new vaccines and discontinuing “optional” immunizations, she remarked following the vote on a online show. At the FDA, Dr. Høeg has reportedly floated the idea of excluding young men from getting COVID-19 vaccinations.

“She is an all-around true believer who commences with her conclusions and tailors the evidence to fit the data in a highly deceptive, fraudulent way,” Dr. Howard argued.

Taking Control and a “Campaign of Retribution”

Dr. Høeg joined other dissenters, {like|